These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 21612462

  • 21. Eculizumab in severe Shiga toxin-mediated haemolytic uraemic syndrome.
    Carroll M, Blake L, Sharma S.
    BMJ Case Rep; 2024 Jan 18; 17(1):. PubMed ID: 38238162
    [Abstract] [Full Text] [Related]

  • 22. The Czech Experience with Eculizumab in Severe Paediatric Shiga Toxin-Producing Escherichia coli-Associated Haemolytic Uremic Syndrome Patients.
    Konopasek P, David J, Marejkova M, Simankova N, Vondrak K, Zieg J.
    Klin Padiatr; 2022 Jan 18; 234(1):48-51. PubMed ID: 33167045
    [No Abstract] [Full Text] [Related]

  • 23. Response to Eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations.
    Saini A, Emke AR, Silva MC, Perlman SJ.
    Clin Pediatr (Phila); 2015 Apr 18; 54(4):387-9. PubMed ID: 24817079
    [No Abstract] [Full Text] [Related]

  • 24. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I, Obermann B, Katalinic A, Eisemann N, Knobloch JK, Sayk F, Wellhöner P, Lehnert H, Solbach W, Süfke S, Steinhoff J, Nitschke M.
    Nephrol Dial Transplant; 2016 Jan 18; 31(1):95-103. PubMed ID: 26180049
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.
    Mody RK, Luna-Gierke RE, Jones TF, Comstock N, Hurd S, Scheftel J, Lathrop S, Smith G, Palmer A, Strockbine N, Talkington D, Mahon BE, Hoekstra RM, Griffin PM.
    Arch Pediatr Adolesc Med; 2012 Oct 18; 166(10):902-9. PubMed ID: 22869280
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The dilemma of antimicrobial treatment of Shiga toxin-producing Escherichia coli.
    Mor M, Ashkenazi S.
    Pediatr Infect Dis J; 2014 Sep 18; 33(9):979-81. PubMed ID: 25361025
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.
    Karpman D.
    Nephrol Dial Transplant; 2012 Oct 18; 27(10):3669-74. PubMed ID: 23114892
    [No Abstract] [Full Text] [Related]

  • 37. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
    Ito K, Hattori M, Matsumoto N.
    Nihon Rinsho; 2002 Jun 18; 60(6):1126-30. PubMed ID: 12078084
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.